Related Experiment Video

Updated: Jun 5, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and

Douglas W McMillin1, Jake Delmore, Joseph Negri

  • 1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Department of Medicine, Harvard Medical School, Boston Novartis Institutes for BioMedical Research, Cambridge, MA 02115, USA.

British Journal of Haematology
|January 13, 2011
PubMed

Insights

A novel multi-targeted cyclin-dependent kinase (CDK) inhibitor, LCQ195, effectively induces cell death in multiple myeloma (MM) cells. This compound shows promise for MM therapy by downregulating key oncogenic pathways and overcoming drug resistance.

Area of Science:

  • Molecular Biology
  • Cancer Therapeutics
  • Hematology

Background:

  • Multiple myeloma (MM) cells exhibit increased proliferation, making cell cycle regulators like cyclin-dependent kinases (CDKs) attractive therapeutic targets.
  • Existing CDK inhibitors may not offer a distinct therapeutic advantage due to their specific activity spectrum.

Purpose of the Study:

  • To investigate the therapeutic potential of a novel multi-targeted CDK inhibitor, NVP-LCQ195/AT9311 (LCQ195), in multiple myeloma (MM).
  • To determine if LCQ195's unique inhibition profile could induce distinct molecular changes with therapeutic implications for MM.

Main Methods:

  • Studied the effects of LCQ195, a small molecule inhibitor targeting CDK1, CDK2, CDK5, CDK3, and CDK9, on MM cells.
  • Assessed LCQ195's impact on cell cycle progression, apoptosis, and transcriptional signatures in MM cells, including those protected by the bone marrow microenvironment.
  • Correlated gene expression profiles suppressed by LCQ195 with patient survival data from bortezomib-treated MM cohorts.

Main Results:

  • LCQ195 induced cell cycle arrest and apoptotic cell death in MM cells at sub-micromolar concentrations, while sparing non-malignant cells.
  • LCQ195 effectively overcame MM cell protection conferred by bone marrow stroma and cytokines.
  • LCQ195 decreased transcriptional signatures associated with oncogenesis, drug resistance, and stem cell renewal, including key transcription factors like MYC, HIF-1α, and IRF4.
  • High baseline expression of LCQ195-suppressed genes in MM tumors correlated with significantly shorter progression-free and overall survival in bortezomib-treated patients.

Conclusions:

  • Multi-targeted CDK inhibition with LCQ195 demonstrates significant anti-myeloma activity, including overcoming microenvironmental protection and downregulating oncogenic pathways.
  • The observed molecular sequelae suggest a strong therapeutic rationale for LCQ195 in multiple myeloma.
  • LCQ195's ability to suppress key oncogenic transcriptional signatures highlights its potential to address drug resistance and improve patient outcomes in MM.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...